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Acinetobacter baumannii is a major opportunistic pathogen in healthcare settings
worldwide. In Iran, there are only few reports on the prevalence of aminoglycoside
resistance genes among A. baumannii isolates. The aim of this study was to investigate the
existence of aminoglycoside-modifying enzyme (AME) genes from A. baumannii strains
collected at a university teaching hospital in Iran. One hundred A. baumannii strains were
collected between 2014 and 2015 from hospitalized patients at Loghman Hakim Hospital,
Tehran, Iran. Antimicrobial susceptibility was determined by disk diffusion method
according to the Clinical and Laboratory Standards Institute recommendations. The DNA
was extracted using a kit obtained from Bioneer Co. (Korea) and was used as a template
for polymerase chain reaction. The most active antimicrobial agent against these strains
was colistin. The rate of extended-spectrum cephalosporin resistance was 97%. The
aadA1, aadB, aac(6′)-Ib, and aac(3)-IIa genes were found in 85%, 77%, 72%, and 68%
of A. baumannii isolates, respectively. This study showed a high prevalence rate of AME
genes in A. baumannii. This prevalence rate has explained that further aminoglycoside
resistance genes may have role in the resistance of clinical isolates of A. baumannii.
Therefore, control and treatment of serious infections caused by this opportunistic
pathogen should be given more consideration.
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Introduction
Acinetobacter baumannii is a major opportunistic, non-fermenting, Gram-
negative pathogen in healthcare settings worldwide, and it is now being isolated at
an increasing rate from wound infections [1]. The organism’s ability to spread
among hospitalized patients and to persist for long periods along with multidrug
resistance are the major driving forces behind the frequent large outbreaks in
different countries [2]. Three decades ago, A. baumannii infections were treated
with traditional antibiotics, but during the past two decades, A. baumannii resistant
to a wide range of antibiotics including aminoglycosides, ﬂuoroquinolones, broad-
spectrum β-lactams, and carbapenems has emerged [3]. They can cause a variety of
nosocomial infections including pneumonia, meningitis, endocarditis, urinary tract
infections, and wound infections especially in hospitalized patients in the intensive
care units (ICUs). As infections with drug-resistant A. baumannii in patients remain
difﬁcult to treat, it is becoming a worldwide threat. Aminoglycosides have long
been used for the treatment of A. baumannii infections and still are an important
alternative for therapy. However, resistance to aminoglycosides has increased in
recent years in these bacteria [4–6]. Aminoglycoside-modifying enzymes (AMEs)
are the most important mechanism of providing aminoglycoside resistance in
A. baumannii clinical strains. Recent studies have shown several resistance
mechanisms to aminoglycosides in A. baumannii including enzymatic inactivation
by acetyltransferases (AACs) and adenyltransferases (AADs), usually found on
transposons and plasmids, which facilitate acquisition of resistance [7–11]. In Iran,
to the best of our knowledge, there are only few reports on the prevalence rate of
AME genes among clinical strains. The aim of this study was to evaluate the
antimicrobial susceptibility of A. baumannii strains and to investigate the existence
of AME genes from the strains collected at the university teaching hospital in Iran.
Materials and Methods
Bacterial isolates
A total of 100 A. baumannii strains were collected between January 2014 and
May 2015 from hospitalized patients at Loghman Hakim Hospital, Tehran, Iran.
The isolates obtained were tested by conventional, well-recognized biochemical
tests including oxidase, motility, and citrate tests as well as their capability to grow
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at 42–44 °C [12]. Polymerase chain reaction (PCR) was performed based on the
method of Hujer et al. [13] for identifying the A. baumannii species.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the Kirby–Bauer disk
diffusion method (Mast Group, Merseyside, UK) according to the Clinical and
Laboratory Standards Institute recommendations [14]. Antimicrobial agents tested
were ciproﬂoxacin (CIP, 30 μg), imipenem (IPM, 10 μg), gentamicin (GEN,
10 μg), amikacin (AK, 30 μg), tetracycline (TET, 10 μg), colistin (CO, 10 μg),
cefepime (CPM, 30 μg), ceftriaxone (CRO, 30 μg), ceftazidime (CAZ, 30 μg), and
meropenem (MRP, 10 μg).
DNA extraction, PCR ampliﬁcation, and DNA sequencing
DNA was extracted using a kit obtained from Bioneer Co. (Korea) and was
used as a template for PCR. Ampliﬁcation was achieved under the following thermal
cycling conditions: 5 min at 94 °C for the initial denaturation followed by 36 cycles of
ampliﬁcation consisting of 45 s at 94 °C, 45 s at 52–58 °C, and 45 s at 72 °C, with 5
min at 72 °C for the ﬁnal extension. Target genes, temperatures of annealing,
amplicons size, and primers used for PCR ampliﬁcation are shown in Table I. Results
of the PCR were compared with positive controls. The PCR products were analyzed
by electrophoresis in a 1%–1.5% vw−1 agarose gel. One of the PCR products was
puriﬁed, and direct sequencing was done. The PCR ampliﬁcation was performed for
AME genes including aadA1, aadB, aac(3)-IIa, and aac(6′)-Ib.
Statistical analysis
This was a descriptive application research study. Statistical analyses were
done by MINITAB16 software. The P value and conﬁdence intervals were ≤0.05
and 95%, respectively.
Results
A. baumannii strains were isolated from 100 hospitalized patients. The
patients included 75 (75%) men and 25 (25%) women. The age range of the study
population was 5–80 years [mean age 42.5 (±10) years]. The patterns of antibiotic
resistance found in A. baumannii isolates showed that resistance to tested
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antibiotics was 70 (70%) to IPM, 70 (70%) to MRP, 80 (80%) to GEN,
37 (37%) to CIP, 85 (85%) to AK, 97 (97%) to CRO, 58 (58%) to TET,
97 (97%) to CPM, 97 (97%) to CAZ, and 0 (0%) to CO (Table II). The most
active antimicrobial agent against these strains was CO with 100% susceptibility.
More than 80% of the isolates resistant against AK and GEN harbored AME
genes. The prevalence rate of AAC genes including aac(6′)-Ib and aac(3)-IIa was
72% and 68%, and the prevalence rate of AAD genes including aadA1 and aadB
was reported to be 85% and 77%, respectively. Sequencing of PCR products for
AAC and AAD genes was conﬁrmed by BLAST in NCBI.
Discussion
A. baumannii has emerged as an etiologic threat for diverse nosocomial
infections. The organism’s ability to spread among hospitalized patients and to
persist for long periods along with multidrug resistance are the major driving
forces behind the frequent large outbreaks in different countries [16–18]. The
increase of A. baumannii strains during recent years, along with rapid progress of
antibacterial resistance, led to this study [1, 19]. Therefore, control, prevention,
and treatment of serious infections caused by this bacteria should be considered,
and there is a need for revising the treatment protocols to decrease the spread of
resistant genes among the clinical isolates. The aadA1, aadB, aac(6′)-Ib, and aac
(3)-IIa genes were found in 85 (85%), 77 (77%), (72) 72%, and (68) 68% of
A. baumannii isolates, respectively. In 2006, a US-based study showed the
prevalence rates of aadA1 and aadB genes were 39% and 48%, respectively,
for multidrug-resistant A. baumannii strains [13]. In 2014, a study from Iran
showed aadA1 and aadB genes in 27.9% and 18.6% of A. baumannii
strains, respectively [4]. Most of the aminoglycoside resistance in A. baumannii
isolates involves the production of AMEs. Previous studies have shown that
genes encoding these enzymes can be present on plasmids, transposons, or within
integron-type structures. The increase in the prevalence rate of aminoglycoside-
encoding genes during past decades emphasizes the probable importance
of these structures in the distribution of aminoglycoside resistance in A. baumannii
isolates as nosocomial pathogens. In a study from the USA, among 313 Enter-
obacteriaceae, aac(6′)-Ib was present in 50.5% of isolates [20]. The aac(6′)-Ib-cr
gene encrypts an aminoglycoside AAC(6′)-Ib variant marked by Trp102Arg and
Asp179Tyr substitutions [15, 21]. These changes afford the new enzyme with the
ability to acetylate ﬂuoroquinolones harboring an unsubstituted piperazinyl group,
such as CIP and norﬂoxacin [22]. Therefore, this gene confers the reduction of
susceptibility to some ﬂuoroquinolones in addition to tobramycin, kanamycin, and
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AK. The results of this study indicated an increase in the prevalence rate of
A. baumannii strains isolated from a university teaching hospital in Iran. The detection
of different resistance genes in this study conﬁrmed a wide distribution of these genes
among A. baumannii strains. The prevalence rate of drug-resistant A. baumannii
strains in hospitalized patients implies that care should be taken while identifying
these isolates, preventing their infections, and selecting for a correct drug treatment
against associated infections. The continuous evaluations on the decrease or increase
of antibiotic resistance among drug-resistant A. baumannii strains could provide the
physicians with new therapeutic choices, so that treatment with ineffectual drugs
would be stopped and replaced by effectual antibiotics. This fact leads to a diminish in
the circulation of drug-resistant A. baumannii isolates among ICU patients. Resistance
among A. baumannii isolates is continuously increasing, so the best decision on the
control of nosocomial infections caused by A. baumannii isolates is the use of
antibiogram tests in each geographic area.
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